Psychedelics and Psychedelic-Assisted Psychotherapy.
(Reprinted with permission from 2020; 177:391-410).
Bibliographic context
Authors
Reiff CMRichman EENemeroff CBCarpenter LLWidge ASRodriguez CIKalin NHMcDonald WMWork Group on Biomarkers and Novel Treatmentsa Division of the American Psychiatric Association Council of Research
Watch author
Topics and keywords
Citation graph
0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.
Indexed papers citing this DOI
Related papers
Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat StressNeuropsychopharmacology Reports · 2026-08-31Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled ConditionsJournal of Fungi · 2026-07-01MDMA and psilocybin therapy rules have been relaxed. Here’s what might happen nextUnknown journal · 2026-06-28Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New MexicoFrontiers in Public Health · 2026-06-16Time to embrace the whole: considering the replacement of psilocybin with Psilocybe spp. in psychedelic research and therapyNatural Product Research · 2026-06-01Corrigendum to “From Prohibited to Prescribed: The Rescheduling of MDMA and Psilocybin in Australia”Drug Science Policy and Law · 2026-05-31EE127 A REVIEW OF HEALTH ECONOMIC ANALYSES OF PSILOCYBIN, MIDOMAFETAMINE(MDMA), AND KETAMINE-BASED TREATMENTS FOR MENTAL HEALTH CAREValue in Health · 2026-05-31Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers.Open Access CRIS of the University of Bern · 2026-05-27